Postmenopausal osteoporosis: an update on current and future therapeutic options

References

• Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr. Mol. Med. 2(6), 571–577 (2002).
   PubMedGoogle Scholar
• Nancollas GH, Tang R, Phipps RJ et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38(5), 617–627 (2006).
   PubMed Web of Science ®Google Scholar
• Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 38(5), 628–636 (2006).
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041), 1535–1541 (1996).
   PubMed Web of Science ®Google Scholar
• Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev. 23(4), 570–578 (2002).
   PubMed Web of Science ®Google Scholar
• Luckey MM, Gilchrist N, Bone HG et al. Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet. Gynecol. 101(4), 711–721 (2003).
   PubMed Web of Science ®Google Scholar
• Schnitzer T, Bone HG, Crepaldi G et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano ) 12(1), 1–12 (2000).
   PubMedGoogle Scholar
• Bone HG, Hosking D, Devogelaer J et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350(12), 1189–1199 (2004).
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282(14), 1344–1352 (1999).
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. 11(1), 83–91 (2000).
   PubMed Web of Science ®Google Scholar
• Roux C, Seeman E, Eastell R et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr. Med. Res. Opin. 20(4), 433–439 (2004).
   PubMed Web of Science ®Google Scholar
• Sorensen OH, Crawford GM, Mulder H et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32(2), 120–126 (2003).
   PubMed Web of Science ®Google Scholar
• Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif. Tissue Int. 75(6), 462–468 (2004).
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med. 344(5), 333–340 (2001).
   PubMed Web of Science ®Google Scholar
• Brown JP, Kendler DL, McClung MR et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif. Tissue Int. 71(2), 103–111 (2002).
   PubMed Web of Science ®Google Scholar
• Watts NB, Lindsay R, Li Z, Kasibhatla C, Brown J. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos. Int. 14(5), 437–441 (2003).
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Ettinger MP, Miller PD et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr. Med. Res. Opin. 21(3), 391–401 (2005).
   PubMed Web of Science ®Google Scholar
• Chesnut III CH, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 19(8), 1241–1249 (2004).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Adami S, Lakatos P et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann. Rheum. Dis. 65(5), 654–661 (2006).
   PubMed Web of Science ®Google Scholar
• Delmas PD, Ensrud KE, Adachi JD et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 87(8), 3609–3617 (2002).
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7), 637–645 (1999).
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J. Bone Miner. Res. 17(1), 1–10 (2002).
   PubMed Web of Science ®Google Scholar
• Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl Cancer Inst. 96(23), 1751–1761 (2004).
   PubMed Web of Science ®Google Scholar
• Grady D, Ettinger B, Moscarelli E et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet. Gynecol. 104(4), 837–844 (2004).
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D, Sashegyi A et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287(7), 847–857 (2002).
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3), 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14), 1701–1712 (2004).
   PubMed Web of Science ®Google Scholar
• Chesnut CH, III, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am. J. Med. 109(4), 267–276 (2000).
   PubMed Web of Science ®Google Scholar
• Lyritis GP, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop. Scand. Suppl. 275, 112–114 (1997).
   PubMedGoogle Scholar
• Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin. Ther. 11(2), 205–209 (1989).
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344(19), 1434–1441 (2001).
   PubMed Web of Science ®Google Scholar
• Cortet B, Bera-Louville A, Gauthier P, Gauthier A, Marchandise X, Delcambre B. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. Effect of adding hormone replacement therapy. Joint Bone Spine 68(5), 410–415 (2001).
   PubMed Web of Science ®Google Scholar
• Davas I, Altintas A, Yoldemir T, Varolan A, Yazgan A, Baksu B. Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women. Fertil. Steril. 80(3), 536–540 (2003).
   PubMed Web of Science ®Google Scholar
• Evio S, Tiitinen A, Laitinen K, Ylikorkala O, Valimaki MJ. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J. Clin. Endocrinol. Metab. 89(2), 626–631 (2004).
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 289(19), 2525–2533 (2003).
   PubMed Web of Science ®Google Scholar
• Lindsay R, Cosman F, Lobo RA et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J. Clin. Endocrinol. Metab. 84(9), 3076–3081 (1999).
   PubMed Web of Science ®Google Scholar
• Tiras MB, Noyan V, Yildiz A, Yildirim M, Daya S. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study. Hum. Reprod. 15(10), 2087–2092 (2000).
   PubMed Web of Science ®Google Scholar
• Ulla MR, Araujo GL, Giglione F et al. Effects on bone mass of oral alendronate, hormone replacement therapy and combined regimes in post-menopausal women: preliminary report on a comparative study. Medicina (B. Aires) 57(Suppl. 1), 49–55 (1997).
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349(13), 1207–1215 (2003).
   PubMed Web of Science ®Google Scholar
• Deal C, Omizo M, Schwartz EN et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res. 20(11), 1905–1911 (2005).
   PubMed Web of Science ®Google Scholar
• Rittmaster RS, Bolognese M, Ettinger MP et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab. 85(6), 2129–2134 (2000).
   PubMed Web of Science ®Google Scholar
• Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Miner. Res. 19(5), 745–751 (2004).
   PubMed Web of Science ®Google Scholar
• Michalska D, Stepan JJ, Basson BR, Pavo I. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 91(3), 870–877 (2006).
   PubMed Web of Science ®Google Scholar
• Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N. Engl. J. Med. 353(6), 566–575 (2005).
   PubMed Web of Science ®Google Scholar
• Body JJ, Gaich GA, Scheele WH et al. A randomized double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone (1–34)) with alendronate in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 87(10), 4528–4535 (2002).
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Hochberg MC, Bonnick SL et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res. 20(1), 141–151 (2005).
   PubMed Web of Science ®Google Scholar
• Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos. Int. 16(7), 842–848 (2005).
   PubMed Web of Science ®Google Scholar
• Thomson AB, Marshall JK, Hunt RH et al. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J. Rheumatol. 29(9), 1965–1974 (2002).
   PubMed Web of Science ®Google Scholar
• Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119(3), 631–638 (2000).
   PubMed Web of Science ®Google Scholar
• Lanza F, Schwartz H, Sahba B et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am. J. Gastroenterol. 95(11), 3112–3117 (2000).
   PubMed Web of Science ®Google Scholar
• Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: A potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90(3), 1294–1301 (2005).
   PubMed Web of Science ®Google Scholar
• Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J. Oral Pathol. Med. 34(10), 613–617 (2005).
   PubMed Web of Science ®Google Scholar
• Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology 66(3), 658E1–658E3 (2005).
   Web of Science ®Google Scholar
• Ke HZ, Qi H, Crawford DT, Chidsey-Frink KL, Simmons HA, Thompson DD. Lasofoxifene (CP–336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology 141(4), 1338–1344 (2000).
   PubMed Web of Science ®Google Scholar
• Komm BS, Kharode YP, Bodine PVN, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146(9), 3999–4008 (2005).
   PubMed Web of Science ®Google Scholar
• Ma YL, Bryant HU, Zeng Q et al. Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J. Bone Miner. Res. 17(12), 2256–2264 (2002).
   PubMed Web of Science ®Google Scholar
• Buzdar A, O’Shaughnessy JA, Booser DJ et al. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 21(6), 1007–1014 (2003).
   PubMed Web of Science ®Google Scholar
• Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 346(9), 653–661 (2002).
   PubMed Web of Science ®Google Scholar
• Polascik TJ, Given RW, Metzger C et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 66(5), 1054–1059 (2005).
   PubMed Web of Science ®Google Scholar
• Tauchmanova L, Ricci P, Serio B et al. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J. Clin. Endocrinol. Metab. 90(2), 627–634 (2005).
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Hanley DA, Ettinger MP et al. Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 88(11), 5212–5220 (2003).
   PubMed Web of Science ®Google Scholar
• Black DM, Bilezikian JP, Ensrud KE et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N. Engl. J. Med. 353(6), 555–565 (2005).
   PubMed Web of Science ®Google Scholar
• Shrader SP, Ragucci KR. Parathyroid hormone (1–84) and treatment of osteoporosis. Ann. Pharmacother. 39(9), 1511–1516 (2005).
   PubMed Web of Science ®Google Scholar
• Moseley JM, Kubota M, Diefenbach-Jagger H et al. Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc. Natl Acad. Sci. USA 84, 5048–5052 (1987).
   PubMed Web of Science ®Google Scholar
• Juppner H, Abou-Samra AB, Freeman M et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254(5034), 1024–1026 (1991).
   PubMed Web of Science ®Google Scholar
• Suda N, Gillespie MT, Traianedes K et al. Expression of parathyroid hormone-related protein in cells of osteoblast lineage. J. Cell. Physiol. 166(1), 94–104 (1996).
   PubMed Web of Science ®Google Scholar
• Dobnig H, Kainer F, Stepan V et al. Elevated parathyroid hormone-related peptide levels after human gestation: relationship to changes in bone and mineral metabolism. J. Clin. Endocrinol. Metab. 80(12), 3699–3707 (1995).
   PubMed Web of Science ®Google Scholar
• Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104(4), 439–446 (1999).
   PubMed Web of Science ®Google Scholar
• Martin TJ. Osteoblast-derived PTHrP is a physiological regulator of bone formation. J. Clin. Invest. 115(9), 2322–2324 (2005).
   PubMed Web of Science ®Google Scholar
• Miao D, Li J, Xue Y, Su H, Karaplis AC, Goltzman D. Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology 145(8), 3554–3562 (2004).
   PubMed Web of Science ®Google Scholar
• Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1–34, parathyroid hormone-related protein 1–36, and SDZ-parathyroid hormone 893. J. Bone Miner. Res. 15(8), 1517–1525 (2000).
   PubMed Web of Science ®Google Scholar
• Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 88(2), 569–575 (2003).
   PubMed Web of Science ®Google Scholar
• Whitfield JF, Morley P, Willick G et al. Cyclization by a specific lactam increases the ability of human parathyroid hormone (hPTH)-(1–31)NH2 to stimulate bone growth in ovariectomized rats. J. Bone Miner. Res. 12(8), 1246–1252 (1997).
   PubMed Web of Science ®Google Scholar
• Morley P, Whitfield JF, Willick GE et al. The effect of monocyclic and bicyclic analogs of human parathyroid hormone (hPTH)-(1–31)NH2 on bone formation and mechanical strength in ovariectomized rats. Calcif. Tissue Int. 68(2), 95–101 (2001).
   PubMed Web of Science ®Google Scholar
• Fraher LJ, Avram R, Watson PH et al. Comparison of the biochemical responses to human parathyroid hormone-(1–31)NH2 and hPTH-(1–34) in healthy humans. J. Clin. Endocrinol. Metab. 84(8), 2739–2743 (1999).
   PubMed Web of Science ®Google Scholar
• Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 341, 19–39 (2004).
   PubMed Web of Science ®Google Scholar
• Gong Y, Slee RB, Fukai N et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107(4), 513–523 (2001).
   PubMed Web of Science ®Google Scholar
• Little RD, Carulli JP, Del Mastro RG et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70(1), 11–19 (2002).
   PubMed Web of Science ®Google Scholar
• van Wesenbeeck L, Cleiren E, Gram J et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am. J. Hum. Genet. 72(3), 763–771 (2003).
   PubMed Web of Science ®Google Scholar
• Boyden LM, Mao J, Belsky J et al. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346(20), 1513–1521 (2002).
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Y, Kang H et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280(20), 19883–19887 (2005).
   PubMed Web of Science ®Google Scholar
• Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J. Cell Sci. 116(Pt 13), 2627–2634 (2003).
   PubMed Web of Science ®Google Scholar
• Warmington KOMBBetal. Sclerostin monoclonal antibody treatment of osteoporotic rats completely reverses one year of ovariectomy-induced systemic bone loss. J. Bone Miner. Res. 20, S22 (2005).
   Google Scholar
• Bekker PJ, Holloway DL, Rasmussen AS et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19(7), 1059–1066 (2004).
   PubMed Web of Science ®Google Scholar
• McClung MR, Lewiecki EM, Cohen SB et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354(8), 821–831 (2006).
   PubMed Web of Science ®Google Scholar
• Whyte MP. The long and the short of bone therapy. N. Engl. J. Med. 354(8), 860–863 (2006).
   PubMed Web of Science ®Google Scholar
• Kafienah W, Bromme D, Buttle DJ, Croucher LJ, Hollander AP. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem. J. 331(Pt 3), 727–732 (1998).
   PubMed Web of Science ®Google Scholar
• Hou WS, Li Z, Gordon RE et al. Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. Am. J. Pathol. 159(6), 2167–2177 (2001).
   PubMed Web of Science ®Google Scholar
• Gowen M, Lazner F, Dodds R et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14(10), 1654–1663 (1999).
   PubMed Web of Science ®Google Scholar
• Saftig P, Hunziker E, Wehmeyer O et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl Acad. Sci. USA 95(23), 13453–13458 (1998).
   PubMed Web of Science ®Google Scholar
• Kiviranta R, Morko J, Uusitalo H, Aro HT, Vuorio E, Rantakokko J. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J. Bone Miner. Res. 16(8), 1444–1452 (2001).
   PubMed Web of Science ®Google Scholar
• Inui T, Ishibashi O, Inaoka T et al. Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J. Biol. Chem. 272(13), 8109–8112 (1997).
   PubMed Web of Science ®Google Scholar
• Motyckova G, Fisher DE. Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. Curr. Mol. Med.. 2(5), 407–421 (2002).
   PubMedGoogle Scholar
• Lark MW, Stroup GB, James IE et al. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone 30(5), 746–753 (2002).
   PubMed Web of Science ®Google Scholar
• Nikawa T, Ikemoto M, Watanabe C et al. A cysteine protease inhibitor prevents suspension-induced declines in bone weight and strength in rats. J. Physiol. Anthropol. Appl. Human Sci. 21(1), 51–57 (2002).
   PubMedGoogle Scholar
• Stroup GB, Lark MW, Veber DF et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J. Bone Miner. Res. 16(10), 1739–1746 (2001).
   PubMed Web of Science ®Google Scholar
• Wang D, Li W, Pechar M, Kopeckova P, Bromme D, Kopecek J. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis. Int. J. Pharm. 277(1–2), 73–79 (2004).
   PubMed Web of Science ®Google Scholar
• Marie PJ. Strontium as therapy for osteoporosis. Curr. Opin. Pharmacol. 5(6), 633–636 (2005).
   PubMed Web of Science ®Google Scholar
• Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18(6), 517–523 (1996).
   PubMed Web of Science ®Google Scholar
• Barbara A, Delannoy P, Denis BG, Marie PJ. Normal matrix mineralization induced by strontium ranelate in MC3T3–E1 osteogenic cells. Metab. Clin. Exp. 53(4), 532–537 (2004).
   PubMed Web of Science ®Google Scholar
• Brown EM. Is the calcium receptor a molecular target for the actions of strontium on bone? Osteoporosis Int. 14, S25–S34 (2003).
   Google Scholar
• Coulombe J, Faure H, Robin B, Tsouderos Y, Ruat M. Stimulatory effects of strontium ranelate (S12911) on the rat and mouse cation-sensing receptor. J. Bone Miner. Res. 16, S428 (2001).
   Google Scholar
• Delannoy P, Bazot D, Robin B, Tsouderos Y, Marie PJ. Long-term treatment with strontium ranelate (S12911) increases vertebral bone mass without deleterious effect in mice. J. Bone Miner. Res. 16, S294 (2001).
   Google Scholar
• Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J. Bone Miner. Res. 19(12), 2012–2020 (2004).
   PubMed Web of Science ®Google Scholar
• Arlot ME, Delmas P, Burt-Pichat B, et.al. The effects of strontium ranelate on bone remodeling and bone safety assessed by histomorphometry in patients with postmenopausal osteoporosis. J. Bone Miner. Res. 20(Suppl. 1), S22 (2006).
   Google Scholar
• Meunier PJ, Slosman DO, Delmas PD et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis – A 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 87(5), 2060–2066 (2002).
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350(5), 459–468 (2004).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90(5), 2816–2822 (2005).
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349(13), 1216–1226 (2003).
   PubMed Web of Science ®Google Scholar
• Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102(8), 1627–1633 (1998).
   PubMed Web of Science ®Google Scholar
• Ma YL, Bryant HU, Zeng Q, Schmidt A, Jee WS, Sato M. Raloxifene and teriparatide (hPTH 1–34) have complementary effects on the osteopenic skeleton of ovariectomized rats. J. Bone Miner. Metab. 23(Suppl.), 62–68 (2005).
   PubMed Web of Science ®Google Scholar